14 Year Old Boy Dies of Acne Treatment, Why Wont They Name the Tablet He Took?
Question by It’s just me.: 14 year old boy dies of acne treatment, why wont they name the tablet he took?
I don’t know if you’ve heard of this, but it made me very untrustful of acne medication and now I’m worried
Why wont they name the drug he took? is this news just a lie?
Article… http://news.bbc.co.uk/2/hi/uk_news/wales/south_east/7697479.stm
Best answer:
Answer by bookish
Sadly, this boy had an allergy to the medication. It can happen. For example, many people have a dangerous allergy to penicillin, but that doesn’t mean nobody should take penicillin.
Give your answer to this question below!
Melanotan (one) “afamelanotide” NBC News report, November 1991 – Melanotan (one) “afamelanotide” discovery by researchers at the University of Arizona in Tucson as explained by NBC News’ Robert Bazell (with Tom Brokaw introduction) in a November 1991 News report. Melanotan (one) is now being developed in Australia as a photoprotective medicine to treat people who’s skin is negatively affected (more than normal) by exposure to UV light. Clinuvel (originally named “Epitan”) is the company that has been working to develop it since 1999. They are currently conducting clinical trials (under the drug name “afamelanotide”). The expected release of Melanotan one on the market as a treatment option for Erythropoietic Protoporphyria (EPP) sufferers is likely to be either 2009 or 2010. Journal of the American Medical Association article that this report was based upon: jama.ama-assn.org www.clinuvel.com en.wikipedia.org melanotan.org afamelanotide
Fungal infection a far-reaching ordeal
Filed under: drug treatment news articles
The drug causes liver inflammation, and for the first 30 minutes of each treatment, images flicker across his eyes. Spencer's situation illustrates many of the challenges public health officials, physicians, and patients are grappling with in …
Read more on Boston.com
PropThink: ACHN Keeps Advancing, Visibility As Leader In Next-Gen HCV …
Filed under: drug treatment news articles
Achillion Pharmaceuticals (NASDAQ:ACHN) is up nearly 80% since its summer lows (see our initial article here), as the hepatitis C (HCV) space continues to evolve. While Gilead's (NASDAQ:GILD) nucleotide ("nuke") treatment candidate GS-7977 continues …
Read more on Reuters
Here's What the FDA Has to Say About Isis Pharmaceuticals
Filed under: drug treatment news articles
Recent trial data released by Isis Pharmaceuticals (NASDAQ:ISIS) showed that the company's treatment for a rare genetic disease caused abnormal growths. A report released Tuesday by the U.S. Food and Drug Administration announced that the regulator …
Read more on Wall St. Cheat Sheet